Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Income from Continuing Operations for 3 consecutive years, with 32834000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 31.4% to 32834000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 140055000.0 through Dec 2025, down 108.3% year-over-year, with the annual reading at 140055000.0 for FY2025, 108.3% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 32834000.0 at Inhibrx Biosciences, up from 35256000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 1858011000.0 in Q2 2024, with the low at 91970000.0 in Q4 2023.
  • Average Income from Continuing Operations over 3 years is 123336909.09, with a median of 43864000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations skyrocketed 4048.85% in 2024, then plummeted 101.54% in 2025.
  • Over 3 years, Income from Continuing Operations stood at 91970000.0 in 2023, then skyrocketed by 47.96% to 47865000.0 in 2024, then surged by 31.4% to 32834000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 32834000.0, 35256000.0, and 28654000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.